DRAVP ID  DRAVPe02089

Peptide Name   S4

Sequence  FNCYFPLQSYGFQPTNGVGYK

Sequence Length  21

UniProt ID  None  

Taxon ID  None 

Source  Synthetic construct

Validation   Experimentally Validated

Gene Name/ID  Not Available

GenBank  Not Available

Amino Acid position  Not Available

Domain Accession ID  Not Available

Nucleotide sequence ID  Not Available

Molecular Type  Not Available

Chromosomal Position  Not Available

Target Organism  SARS-CoV-2

Assay  SARS-CoV-2 inhibition assay

Activity 

• [Ref:38917689] PT (Vero E6): EC50 = 4.40 µM (TI = 163.68), BA.2 (Vero E6): EC50 = 4.87 µM (TI = 147.88), EG.5 (Vero E6): EC50 = 8.44 µM (TI = 85.33), XBB.1.16 (Vero E6): EC50 = 9.59 µM (TI = 75.10)

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

• [Ref:38917689]PT(Vero E6): CC₅₀=720.20 µM,BA.2 (Vero E6): CC₅₀=720.20 µM,EG.5 (Vero E6): CC₅₀= 720.20 µM,XBB.1.16 (Vero E6): CC₅₀= 720.20 µM,HEK293T: CC₅₀=730.20 µM,HEK293T/ACE2: CC₅₀=714.0 µM

Binding Target  Not given

Mechanism  peptide S4 inhibited the ACE2 receptor and competed with the HCoV-NL63 virus for binding while exhibiting good inhibitory activity against HCoV-NL63 infection.

PDB ID  None

Predicted Structure Download  No predicted structure available

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L

Literature 1

Title   Peptide S4 is an entry inhibitor of SARS-CoV-2 infection

Pubmed ID   38917689

Reference   Virology, 597, 110149.

Author   Liang, Z., Wang, J., Zhang, H., Gao, L., Xu, J., Li, P., Yang, J., Fu, X., Duan, H., Liu, J., Liu, T., Ma, W., & Wu, K.

DOI   10.1016/j.virol.2024.110150